| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0002-9343(02)01476-6 |
| P8608 | Fatcat ID | release_akqqn6dnifdmpgw5i46lt3nupm |
| P698 | PubMed publication ID | 12637133 |
| P2093 | author name string | Abraham Danon | |
| Carmi Bartal | |||
| Michael Alkan | |||
| Francisc Schlaeffer | |||
| Yaniv Almog | |||
| Aviel Sidi | |||
| Klaris Reisenberg | |||
| Rosa Smoliakov | |||
| P2860 | cites work | Once daily aminoglycoside therapy. Is it less toxic than multiple daily doses and how should it be monitored? | Q33545113 |
| First-exposure adaptive resistance to aminoglycoside antibiotics in vivo with meaning for optimal clinical use. | Q36752618 | ||
| Once versus thrice daily gentamicin in patients with serious infections | Q39369365 | ||
| Parenteral aminoglycoside therapy. Selection, administration and monitoring | Q40392377 | ||
| Once-daily dosing of aminoglycosides: review and recommendations for clinical practice | Q41530531 | ||
| Comparison of two Bayesian approaches to dose-individualization for once-daily aminoglycoside regimens | Q42625076 | ||
| Characteristics and outcomes in adult patients receiving mechanical ventilation: a 28-day international study | Q43489748 | ||
| Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration | Q44483617 | ||
| Adaptation in neonatology of the once-daily concept of aminoglycoside administration: evaluation of a dosing chart for amikacin in an intensive care unit | Q44886328 | ||
| Once-daily dosing of aminoglycosides | Q46860894 | ||
| The pharmacokinetics of amikacin in critically ill adult and paediatric patients: comparison of once- versus twice-daily dosing regimens | Q46960940 | ||
| American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference | Q55879451 | ||
| Gentamicin volume of distribution in critically ill septic patients | Q57238214 | ||
| The inductive role of ionic binding in the bactericidal and postexposure effects of aminoglycoside antibiotics with implications for dosing | Q68343992 | ||
| Aminoglycoside nephrotoxicity | Q68880891 | ||
| Amikacin pharmacokinetics: wide interpatient variation in 98 patients | Q70129560 | ||
| Initial aminoglycoside levels in the critically ill | Q71098846 | ||
| Experience of once-daily aminoglycoside dosing using a target area under the concentration-time curve | Q71559681 | ||
| Gentamicin once a day | Q73078387 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pharmacokinetics | Q323936 |
| P304 | page(s) | 194-198 | |
| P577 | publication date | 2003-02-01 | |
| P1433 | published in | American Journal of Medicine | Q2842959 |
| P1476 | title | Pharmacokinetic dosing of aminoglycosides: a controlled trial | |
| P478 | volume | 114 |
| Q51813710 | Acute kidney injury in non-critically ill children treated with aminoglycoside antibiotics in a tertiary healthcare centre: a retrospective cohort study. |
| Q26745670 | Acute kidney injury in the perioperative period and in intensive care units (excluding renal replacement therapies) |
| Q42133019 | Adsorption of amikacin, a significant mechanism of elimination by hemofiltration |
| Q30830192 | Aerosolized amikacin for treatment of pulmonary Mycobacterium avium infections: an observational case series |
| Q38239999 | Aminoglycoside-induced nephrotoxicity--a focus on monitoring: a review of literature |
| Q38090988 | Aminoglycosides in septic shock: an overview, with specific consideration given to their nephrotoxic risk |
| Q28068503 | Antimicrobial Stewardship: How the Microbiology Laboratory Can Right the Ship |
| Q36263480 | Antimicrobial therapy in critically ill patients: a review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability |
| Q38125209 | Approaches for dosage individualisation in critically ill patients. |
| Q84629245 | Appropriate antibiotic dosage levels in the treatment of severe sepsis and septic shock |
| Q37636910 | Appropriate use of antimicrobials: the peculiarity of septic patients |
| Q40586961 | Augmenting effect of antibiotics on endotoxin activity may cause a safety problem. |
| Q37701873 | Bile-mediated aminoglycoside sensitivity in Lactobacillus species likely results from increased membrane permeability attributable to cholic acid |
| Q82846837 | Clinical doses of amikacin provide more effective suppression of the human CFTR-G542X stop mutation than gentamicin in a transgenic CF mouse model |
| Q46728031 | Comparative pharmacokinetics of amikacin in Greyhound and Beagle dogs. |
| Q24202497 | Computerized advice on drug dosage to improve prescribing practice |
| Q37050322 | Designer aminoglycosides: the race to develop improved antibiotics and compounds for the treatment of human genetic diseases |
| Q26853629 | Dose optimisation of antibiotics in children: application of pharmacokinetics/pharmacodynamics in paediatrics |
| Q39015529 | Estimating drug-free period using a graphical method: an alternative way to monitor extended-interval dosing of gentamicin therapy |
| Q90582364 | Evaluation of aminoglycosides utilization in intensive care units of a teaching hospital in southern Iran |
| Q45978260 | Evaluation of population pharmacokinetic models for amikacin dosage individualization in critically ill patients. |
| Q51423932 | Factors affecting gentamicin penetration in lower extremity ischemic tissues with ulcers. |
| Q43263735 | Gentamicin-associated acute kidney injury |
| Q34894900 | How do we use therapeutic drug monitoring to improve outcomes from severe infections in critically ill patients? |
| Q37220711 | Implementing an Antibiotic Stewardship Program: Guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America |
| Q27673672 | Inhibition of aminoglycoside-deactivating enzymes APH(3')-IIIa and AAC(6')-Ii by amphiphilic paromomycin O2''-ether analogues |
| Q35675979 | Management of infectious complications in the hematopoietic stem cell transplant recipient |
| Q42556968 | Once versus individualized multiple daily dosing of aminoglycosides in critically ill patients |
| Q73127392 | Once-daily dosing of aminoglycosides: how much monitoring is truly required? |
| Q33949330 | Outcomes in patients with gram-negative sepsis treated with gentamicin |
| Q35623060 | Pharmacodynamics and dosing of aminoglycosides |
| Q36068683 | Pharmacokinetic considerations in the treatment of tuberculosis in patients with renal failure |
| Q47332682 | Pharmacokinetics and pharmacogenetics of anti-tubercular drugs: a tool for treatment optimization? |
| Q37557851 | Pharmacological rationale for antibiotic treatment of intra-abdominal infections |
| Q36975688 | Plasma Peak and Trough Gentamicin Concentrations in Hospitalized Horses Receiving Intravenously Administered Gentamicin |
| Q36366980 | Providing guidelines and education is not enough: an audit of gentamicin use at The Royal Melbourne Hospital |
| Q84013368 | Rational dosing of antimicrobial agents: pharmacokinetic and pharmacodynamic strategies |
| Q38070006 | Rational use of aminoglycosides--review and recommendations by the Swedish Reference Group for Antibiotics (SRGA). |
| Q39030684 | Reduced Chance of Hearing Loss Associated with Therapeutic Drug Monitoring of Aminoglycosides in the Treatment of Multidrug-Resistant Tuberculosis |
| Q33919190 | Revisiting the loading dose of amikacin for patients with severe sepsis and septic shock |
| Q41948736 | Stability and antimicrobial effect of amikacin-loaded solid lipid nanoparticles |
| Q37929895 | The strategy of antibiotic use in critically ill neutropenic patients |
| Q27009221 | Therapeutic drug monitoring for triazoles: A needs assessment review and recommendations from a Canadian perspective |
| Q38790740 | Therapeutic drug monitoring of anti-infective agents in critically ill patients |
| Q51092520 | Therapeutic drug monitoring of once daily aminoglycoside dosing: comparison of two methods and investigation of the optimal blood sampling strategy. |
| Q36925002 | Usage Pattern and Serum Level Measurement of Amikacin in the Internal Medicine Ward of the Largest Referral Hospital in the South of Iran: A Pharmacoepidemiological Study |
| Q81949918 | [The pharmacokinetics of metronidazole and gentamicin in a single preoperative dose as antibiotic prophylaxis in colorectal surgery] |
Search more.